Laboratory of Vaccinology and Mucosal Immunity, Université Libre de Bruxellesgrid.4989.c, Brussels, Belgium.
Department of Infectious Diseases, Centre Hospitalier Universitaire Saint-Pierre, Université Libre de Bruxellesgrid.4989.c, Brussels, Belgium.
J Clin Microbiol. 2022 May 18;60(5):e0244321. doi: 10.1128/jcm.02443-21. Epub 2022 Apr 18.
Optimal detection of latent tuberculosis (TB) infection (LTBI) remains a challenge, although it is essential to reach the goal of TB elimination. Our objective was to develop and clinically evaluate a user-friendly, 24-h, whole-blood (WB) interferon gamma (IFN-γ) release assay (IGRA) improving the detection of LTBI, compared to available tests. One milliliter of blood was divided into four aliquots and stimulated for 24 h with two different stage-specific mycobacterial antigens, i.e., heparin-binding hemagglutinin (HBHA) and early secreted antigenic target 6 (ESAT-6), a latency-associated antigen and a bacterial replication-related antigen, respectively, in addition to positive and negative controls. Clinical evaluation was performed on two independent cohorts of carefully selected subjects, i.e., a training cohort of 83 individuals and a validation cohort of 69 individuals. Both cohorts comprised LTBI subjects (asymptomatic people with a positive tuberculin skin test result and potential exposure to TB index cases), patients with active TB (aTB), and noninfected controls. The sensitivity and specificity of the WB-HBHA-IGRA to identify LTBI subjects among asymptomatic individuals were 93%. Combining the results in response to HBHA and ESAT-6 allowed us to identify LTBI subgroups. One group, with IFN-γ responses to HBHA only, was easily differentiated from patients with aTB. The other group, responding to both antigens like the aTB group, is likely at risk to reactivate the infection and should be prioritized for prophylactic anti-TB treatment. The combined WB-IGRA may be offered to clinicians for the selection of LTBI subjects to benefit from prophylactic treatment.
优化潜伏性结核感染(LTBI)的检测仍然是一个挑战,尽管这对于实现结核病消除目标至关重要。我们的目标是开发一种易于使用的、24 小时的全血(WB)干扰素γ(IFN-γ)释放检测(IGRA),与现有检测方法相比,提高 LTBI 的检测率。将 1 毫升血液分成四份,分别用两种不同的阶段特异性分枝杆菌抗原(即肝素结合血凝素(HBHA)和早期分泌抗原靶 6(ESAT-6))进行 24 小时刺激,此外还包括阳性和阴性对照。临床评估在两个独立的精选受试者队列中进行,即 83 名训练队列和 69 名验证队列。两个队列均包括 LTBI 受试者(无症状者,结核菌素皮肤试验阳性且有接触结核病病例的潜在暴露史)、活动性结核病(aTB)患者和未感染者。WB-HBHA-IGRA 对识别无症状个体中的 LTBI 受试者的敏感性和特异性为 93%。结合对 HBHA 和 ESAT-6 的反应结果,我们能够识别 LTBI 亚组。一组仅对 HBHA 有 IFN-γ 反应,与 aTB 患者很容易区分。另一组对两种抗原的反应与 aTB 组相似,可能有感染复发的风险,应优先进行预防性抗结核治疗。联合 WB-IGRA 可提供给临床医生,用于选择 LTBI 患者以受益于预防性治疗。